In a 58-year-old man with type 2 diabetes and LVH and microalbuminuria, what is the most appropriate initial treatment to address microalbuminuria?

In a 58-year-old man with type 2 diabetes and LVH and microalbuminuria, what is the most appropriate initial treatment to address microalbuminuria?

• A. Initiate a beta-blocker
• B. Initiate a statin
• C. Increase salt intake
• D. Initiate an ACE inhibitor

Answer: (D)

Blockade of the renin-angiotensin system with an ACE inhibitor is the best initial approach for addressing microalbuminuria in a patient with type 2 diabetes. ACE inhibitors reduce intraglomerular pressure by dilating the efferent arteriole, which lowers the leakage of albumin into the urine and slows the progression of diabetic nephropathy. They also help lower blood pressure and can provide favorable effects on left ventricular hypertrophy, offering cardiovascular and renal protection. This makes them the first-line choice specifically for microalbuminuria, even if blood pressure isn’t severely elevated. Start with a low dose and titrate, while monitoring kidney function and potassium. Increasing salt intake would worsen albuminuria, and beta-blockers or statins address other risk factors but do not directly protect the kidneys from microalbuminuria as effectively as an ACE inhibitor.

Blockade of the renin-angiotensin system with an ACE inhibitor is the best initial approach for addressing microalbuminuria in a patient with type 2 diabetes. ACE inhibitors reduce intraglomerular pressure by dilating the efferent arteriole, which lowers the leakage of albumin into the urine and slows the progression of diabetic nephropathy. They also help lower blood pressure and can provide favorable effects on left ventricular hypertrophy, offering cardiovascular and renal protection. This makes them the first-line choice specifically for microalbuminuria, even if blood pressure isn’t severely elevated. Start with a low dose and titrate, while monitoring kidney function and potassium. Increasing salt intake would worsen albuminuria, and beta-blockers or statins address other risk factors but do not directly protect the kidneys from microalbuminuria as effectively as an ACE inhibitor.